ALX Oncology Holdings Inc. (ALXO) Financials

ALXO Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 160.8 million 24.6 million
March 31, 2026 178.3 million 27.0 million
Dec. 31, 2025 59.0 million 33.1 million
Sept. 30, 2025 82.7 million 37.9 million

ALXO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -16.1 million 2.7 million
March 31, 2026 -18.7 million 2.5 million
Dec. 31, 2025 -19.0 million 2.7 million
Sept. 30, 2025 -17.1 million 2.5 million

ALXO Net Income

No data available :(

ALXO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 138.2 million 9.7 million -
March 31, 2026 140.3 million - -
Dec. 31, 2025 44.8 million - -
Sept. 30, 2025 60.6 million - -

ALXO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 135.6 million
March 31, 2026 104.6 million
Dec. 31, 2025 54.3 million
Sept. 30, 2025 53.6 million

ALXO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 17000 13.1 million 5.1 million -
March 31, 2026 50000 13.6 million 5.4 million -
Dec. 31, 2025 49000 17.6 million 5.4 million -
Sept. 30, 2025 56000 17.4 million 5.1 million -

ALXO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 150000
Dec. 31, 2025 - -
Sept. 30, 2025 - -

ALXO

Price: $1.96

52 week price:
0.60
2.66

Earnings Per Share: -1.11 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 63179

Market Capitalization: 268.3 million

Links: